| Shuxian Qu,Zhaozhe Liu,Zhendong Zheng,Zhenyu Ding,Tao Han,Fang Guo,Jianing Qiu,Xiaodong Xie,Dongchu Ma. The influence of autologous cytokine-induced killer cell treatment on the objective efficacy and safety of gefitinib in advanced non-small cell lung cancer. Oncol Transl Med, 2015, 1: 69-72. |
| The influence of autologous cytokine-induced killer cell treatment on the objective efficacy and safety of gefitinib in advanced non-small cell lung cancer |
| Received:January 12, 2015 Revised:April 07, 2015 |
| View Full Text View/Add Comment Download reader |
| KeyWord:non-small cell lung cancer (NSCLC); gefitinib; cytokine-induced killer (CIK) cell |
| Author Name | Affiliation | E-mail | | Shuxian Qu | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | qushuxian2010@163.com | | Zhaozhe Liu | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | doctor_xxd@163.com | | Zhendong Zheng | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | doctor_xxd@163.com | | Zhenyu Ding | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | doctor_xxd@163.com | | Tao Han | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | doctor_xxd@163.com | | Fang Guo | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | doctor_xxd@163.com | | Jianing Qiu | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | doctor_xxd@163.com | | Xiaodong Xie | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | doctor_xxd@163.com | | Dongchu Ma | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | mdc580819@sina.com |
|
| Hits: 6854 |
| Download times: 7557 |
| Abstract: |
| Objective: The aim of the study was to observe the influence of autologous cytokine-induced killer cell (CIK) treatment on the objective efficacy and safety of gefitinib in advanced non-small cell lung cancer (NSCLC).
Methods: Sixty-six patients with NSCLC received gefitinib as second-line treatment. They were randomly divided into 2 groups, and informed consent forms were signed before grouping. Gefitinib was administrated to the control group, and autologous CIK treatment was added to the observation group. The objective treatment and adverse reactions were evaluated in both groups.
Results: The objective response rate (ORR) and the disease control rate (DCR) of the observation group were slightly higher than those of the control group, although no statistical differences were found between the 2 groups (P > 0.05). The incidences of diarrhea, fatigue, anorexia, oral ulcers, and myelosuppression in the observation group were much lower than those in the control group (P < 0.05). However, there were no statistical differences between the incidences of skin rash, and liver and kidney toxicities (P > 0.05).
Conclusion: Autologous CIK in combination with gefitinib is effective as second-line treatment for advanced NSCLC, and can significantly reduce adverse reactions and improve the objective efficacy. |
| Close |
|
|
|